Less cough with candesartan cilexetil than enalapril

被引:0
|
作者
机构
关键词
Placebo; Placebo Group; Hypertensive Patient; Enalapril; Severity Score;
D O I
10.2165/00128415-200007950-00012
中图分类号
学科分类号
摘要
引用
收藏
页码:5 / 5
相关论文
共 50 条
  • [42] Candesartan cilexetil-induced severe hepatotoxicity
    Basile, G
    Villari, D
    Gangemi, S
    Ferrara, T
    Accetta, MG
    Nicita-Mauro, V
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 36 (03) : 273 - 275
  • [44] Candesartan cilexetil: An angiotensin II receptor blocker
    Stoukides, CA
    McVoy, HJ
    Kaul, AF
    ANNALS OF PHARMACOTHERAPY, 1999, 33 (12) : 1287 - 1298
  • [46] Tolerability of a modern antihypertensive agent: candesartan cilexetil
    Andersson, OK
    BASIC RESEARCH IN CARDIOLOGY, 1998, 93 : 54 - 58
  • [47] Candesartan cilexetil: a review of its preclinical pharmacology
    Nishikawa, K
    Naka, T
    Chatani, F
    Yoshimura, Y
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S9 - S17
  • [48] INCREASING SOLUBILITY AND DISSOLUTION RATE OF CANDESARTAN CILEXETIL
    Gruberova, L.
    Kratochvil, B.
    Seilerova, L.
    PROCEEDINGS OF THE 3RD INTERNATIONAL CONFERENCE ON CHEMICAL TECHNOLOGY, 2015, : 150 - 155
  • [49] Angiotensin II receptor antagonists: Candesartan cilexetil
    Naka, T
    Kubo, K
    Nishikawa, K
    Inada, Y
    Furukawa, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2000, 120 (12): : 1261 - 1275
  • [50] Candesartan cilexetil in the treatment of chronic heart failure
    Baguet, Jean-Philippe
    Barone-Rochette, Gilles
    Neuder, Yannick
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 257 - 264